Intangible Assets

GKOS benefits from FDA-cleared, procedure-specific ophthalmic devices and consumables that are tied to surgeon training and clinical evidence, which makes its product set harder to displace than generic capital equipment peers.

Its iStent and related glaucoma offerings are embedded in a specialized treatment workflow, so peer alternatives must overcome physician familiarity and published outcomes rather than compete on price alone.

Compared with broader medtech peers, GKOS has a narrower but more clinically differentiated portfolio, which supports durability in premium niches even though the underlying technology is still replicable over time.

The moat is reinforced by regulatory and clinical validation barriers, but these barriers are weaker than in platform-like medtech franchises because competitors can pursue adjacent device approvals and alternative surgical approaches.

Switching Costs

Surgeons and ambulatory centers incur training, protocol, and inventory adjustment costs when changing glaucoma systems, which creates retention beyond a single purchase cycle.

GKOS’s consumable-plus-capital model can lock in repeat usage after adoption, whereas peers selling one-time devices face weaker post-sale stickiness.

Switching costs are meaningful because clinical teams value consistency in procedure setup and outcomes, but they are lower than in highly integrated implant ecosystems where replacement would disrupt core hospital workflows.

Relative to peers in ophthalmic devices, GKOS has better workflow stickiness than commodity device makers, yet customers can still trial competing products without abandoning an entire care platform.

Network Effects

GKOS does not exhibit a true network effect because one surgeon’s adoption does not materially increase the value of the product for other users in the way a platform or marketplace would.

Clinical evidence and peer-to-peer surgeon familiarity can accelerate adoption, but that is an indirect reputation effect rather than a self-reinforcing network moat.

Compared with software or data-network peers, GKOS lacks ecosystem scale that would compound usage into stronger pricing power or retention.

Any referral or training halo is modest and does not create the kind of peer dependency that would materially protect margins over 5–10 years.

Cost Advantage

GKOS does not appear to have a durable structural cost advantage because its products are specialized medical devices rather than high-volume manufacturing platforms with clear scale economics.

Gross-margin support comes more from clinical differentiation and reimbursement positioning than from a lower cost base versus peers.

Compared with larger diversified medtech competitors, GKOS is less likely to outcompete on procurement scale or manufacturing leverage, which limits long-run pricing flexibility.

Any cost advantage is therefore modest and product-specific, not broad enough to materially outperform peers across the cycle.

Efficient Scale

GKOS operates in a specialized glaucoma niche where the addressable market is limited, which can reduce the number of viable large-scale competitors and support some local efficiency.

The company’s focused portfolio can be more efficient than broad medtech peers in serving a narrow clinical use case, but the market is not so small that competition is structurally excluded.

Efficient scale is constrained because adjacent ophthalmic and surgical device companies can still target the same procedures with alternative technologies.

Relative to peers, GKOS has niche focus advantages, but the category is not protected enough to qualify as a strong efficient-scale moat.

Overall Score

GKOS has a durable but not dominant moat, with its strongest defenses coming from clinical differentiation, regulatory barriers, and moderate switching costs rather than network effects or cost leadership; compared with peers, this supports niche pricing power and retention, but the franchise remains replaceable over a 5–10 year horizon by credible alternative devices and surgical approaches.